Controversies in the management of ASCUS and AGCUS: Two very different beasts

Current Problems in Obstetrics, Gynecology and Fertility

Volumn 24, Issue 1, 2001, Pages 6-23

  Bernard Pearl, L ^a   Smith Mccune, K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CURETTAGE; DISEASE CLASSIFICATION; ENDOMETRIUM BIOPSY; FEMALE; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; PAPANICOLAOU TEST; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; RISK ASSESSMENT; SCREENING TEST; SQUAMOUS CELL; TREATMENT PLANNING; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0035104885     PISSN: 87560410     EISSN: None     Source Type: Journal    
DOI: 10.1067/mog.2001.109513     Document Type: Article

References (123)

1. Estimates of the worldwide incidence of eighteen major cancers in 1985
2. Screening for cervical cancer
3. The diagnostic value of vaginal smears in carcinoma of the uterus
4. Cervical cancer screening: The abnormal pap smear
5. Cancer statistics, 2000
6. Review of the screening history of Alberta women with invasive cervical cancer
7. The cytological screening history of 469 patients with squamous cell carcinoma of the cervix uteri: Does interval carcinoma exist?
8. Screening history of incident cases of invasive carcinoma of the cervix. Florence district 1988-1989
9. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC)
10. High-grade squamous intraepithelial lesions and invasive carcinoma following the report of three negative Papanicolaou smears: Screening failures or rapid progression?
11. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. Developed and approved at the National Cancer Institute Workshop, Bethesda, Maryland, USA,
12. Primary adenocarcinoma of the cervix
13. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
14. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription
15. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
16. Association of human papillomavirus types 16 and 18 E6 proteins with p53
17. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
18. Efficiency of binding of the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
19. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation
20. HPV16 E7 oncoprotein deregulates B-myb expression: Correlation with targeting of pl07/E2F complexes
21. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130
22. Disruption of the El and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis
23. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer
24. Human papillomaviruses and cervical neoplasia: A model for carcinogenesis
25. The molecular pathogenesis of cervical cancer: The role of human papillomaviruses
26. The epidemiology of cervical carcinogenesis
27. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
28. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student healthcenter
29. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon
30. Seroprevalence of human papillomavirus type 16 in pregnant women
31. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions
32. Natural history of cervical intraepithelial neoplasia: A critical review
33. Controversies in the management of low-grade cervical intraepithelial neoplasia
34. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses National Cancer Institute Workshop
35. A modified terminology for cervical intraepithelial neoplasia
36. The Bethesda system for reporting cervical/vaginal cytologic diagnoses - Report of the 1991 Bethesda workshop
37. The Bethesda system for reporting cervical vaginal cytologic diagnoses: Definitions, criteria, and explanatory notes for terminology and specimen adequacy
38. ASCUS and AGCUS criteria. International Academy of Cytology Task Force summary. Diagnostic cytology toward the 21st century: An international expert conference and tutorial
39. Why, how, and when the cytological diagnosis of ASCUS should be eliminated
40. The Bethesda system for cervical/vaginal cytologic diagnoses: A note of caution
41. Use of statistical analysis of cytologic interpretation to determine the causes of interobserver disagreement and in quality improvement
42. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types
43. The "ASCUS" swamp
44. Atypical squamous cells of undetermined significance: Interlaboratory comparison and quality assurance monitors
45. Interobserver variability of cervical smears with squamous-cell abnormalities: A Philadelphia study
46. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance
47. Interim guidelines for management of abnormal cervical cytology
48. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review
49. Low-grade Papanicolaou smears and the Bethesda system: A prospective cytohistopathologic analysis
50. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities
51. Should all women with cervical atypia be referred for colposcopy: A HARNET study. Harrisburgh area research network
52. Evaluation of the atypical cytologic smear. Validity of the 1991 Bethesda system
53. Atypical squamous cells of undetermined significance: Correlative histologic and follow-up studies from an academic medical center
54. Atypical cervical cytology. Colposcopic follow-up using the Bethesda system
55. Prevalence of cervical intraepithelial neoplasia grade 2 or 3 in patients with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions
56. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results
57. Comparison of the hybrid capture test and polymerase chain reaction in identifying women who have an atypical squamous cell of undetermined significance Papanicolaou smear and need colposcopy
58. Long-term outcome and relative risk in women with atypical squamous cells of undetermined significance
59. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions
60. Cervicography combined with repeat Papanicolaou test as triage for low-grade cytologic abnormalities
61. Incidence and predictors of cervical dysplasia in patients with minimally abnormal Papanicolaou smears
62. Atypical squamous cells of undetermined significance: Management patterns at an academic medical center
63. Review of outcomes of atypical squamous cells of undetermined significance Papanicolaou smears for 1991 and 1992, with follow-up through 1995
64. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing
65. ASCUS on cervical cytologic smears. Clinical significance
66. Atypical squamous cells of undetermined significance. A cytohistologic study of 52 cases
67. ThinPrep Pap test. Accuracy for glandular disease
68. Importance of atypical glandular cells of uncertain significance in cervical cytologic smears
69. Cervical cytology: Evaluation and management of abnormalities, ACOG technical bulletin number 183 - August 1993
70. NCCN practice guidelines for cervical cancer screening
71. ASCCP Practice guidelines: Management of glandular abnormalities in the cervical smear
72. Management guidelines for the follow-up of atypical squamous cells of undetermined significance (ASCUS)
73. Does the system of Papanicolaou test nomenclature affect the rate of referral for colposcopy? A survey of family physicians
74. Survey of colposcopy practices by obstetricians/gynecologists
75. Gynaecological care of women with abnormal pap smears: How varied is current practice?
76. The management of women with initial minor pap smear abnormalities
77. The cost-effectiveness of treating women with a cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance
78. Atypical squamous cells of undetermined significance qualified: A follow-up study
79. Atypical squamous cells: Is subclassification worthwhile [abstract]?
80. "ASCUS, rule out HSIL": Cytologic features, histologic correlates, and human papillomavirus detection
81. Qualification of atypical squamous cells of undetermined significance in an independent laboratory: Is it useful or significant?
82. Do qualifiers of ASCUS distinguish between low- and high-risk patients?
83. Atypical squamous cells of undetermined significance: A cytohistological study in a colposcopy clinic
84. Subclassifying atypical squamous cells in Thin-Prep cervical cytology correlates with detection of high-risk human papillomavirus DNA
85. Viral testing for genital human papillomavirus infections: Recent progress and clinical potentials
86. The triage of women with ASCUS cytology using human papillomavirus DNA testing
87. Hybrid capture human papillomavirus testing as an adjunct to the follow-up of patients with ASCUS and LGSIL pap smears: A study of a screening population
88. Predictors of concomitant cervical intraepithelial neoplasia in women with newly diagnosed atypical squamous cells of undetermined significance
89. Triage of women with ASCUS and LSIL on pap smear reports: Management by repeat pap smear, HPV DNA testing, or colposcopy?
90. Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study
91. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL
92. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial
93. Natural history of cervicovaginal papillomavirus infection in young women
94. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
95. Simultaneous effects of aneuploidy and oncogenic human papillomavirus on histological grade of cervical intraepithelial neoplasia
96. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
97. Role of HPV testing in secondary and primary screening of cervical neoplasia
98. Time interval effect on repeat cervical smear results
99. Cigarette smoking and cancer of the uterine cervix
100. Smoking and cervical cancer - Current status: A review
101. Cigarette smoking as a potential cause of cervical cancer: Has confounding been controlled?
102. Condyloma and cervical intraepithelial neoplasia of the uterine cervix: A case-control study
103. Risk factors for cervical intraepithelial neoplasia: Differences between low- and high-grade lesions
104. Management of cervical neoplasia in human immunodeficiency virus-infected women
105. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases
106. Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus
107. Women and HIV. Epidemiology and global overview
108. The impact of the human immuno-deficiency virus on the human papillomavirus epidemic
109. Immunodeficiency virus infection and invasive carcinoma
110. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts
111. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses
112. Use of speculoscopy in the evaluation of women with atypical Papanicolaou smears. Improved cost effectiveness by selective colposcopy
113. Cervicography and HPV DNA testing as triage criteria for patients with abnormal pap smear
114. Cervicography: An intermediate triage test for the evaluation of cervical atypia
115. Cervicography screening for cervical cancer among 8460 women in a high-risk population
116. Spectroscopic diagnosis of cervical intraepithelial neoplasia (CIN) in vivo using laser-induced fluorescence spectra at multiple excitation wave-lengths
117. Development of a multivariate statistical algorithm to analyze human cervical tissue fluorescence spectra acquired in vivo
118. Fluorescence spectroscopy: A diagnostic tool for cervical intraepithelial neoplasia (CIN)
119. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication
120. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy
121. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: Sensitivity, specificity, and cost-effectiveness